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ABSTRACT
Uptake of the H2-receptor antagonist, cimetidine, into syncytial 
microvillus membrane vesicles of human term placenta was 
investigated to clarify whether an active transport mechanism 
can be responsible for the observed barrier of the human 
placenta for cimetidine. Imposition of an outwardly directed 
H+-gradient stimulated cimetidine uptake, resulting in a small 
transient overshoot. The H+-gradient-dependent peak uptake 
was decreased under voltage-clamped conditions by carbonyl 
cyanide p-trifluoromethoxy-phenylhydrazone, suggesting the 
presence of an organic cation-proton exchange mechanism. 
Uptake was partially, but significantly, inhibited by organic ca­
tion transport inhibitors, H2-receptor antagonists and several 
other cationic drugs, providing further evidence for mediated 
uptake. H+-qradient-dependent cimetidine uptake was satura­
ble and characterized by a low-affinity (Km) of 6.3 mM and Vmax 
of 17.5 nmol/mg protein/10 sec. We conclude that the system 
cannot play an important role in the barrier function of the 
human placenta in the transport of cimetidine. Rather than 
active transport, other factors, as for instance the degree of 
ionization of cimetidine at physiological pH, seem to be a more 
likely explanation for the low clearance of cimetidine across the 
human placenta.
H2-receptor antagonists, like cimetidine and ranitidine, 
are frequently used therapeutic agents in the treatment of 
peptic ulcer in humans. Additionally, cimetidine is some­
times used in the prevention of gastric acid aspiration for 
women at labor under general anesthesia (McGowan, 1979).
The guanidine analogs, ranitidine (Mihaly et al., 1982) and 
cimetidine (Mihaly et aL, 1983) cross the placenta in preg­
nant ewes at near term. Fetal plasma concentrations, how­
ever, were much lower than  m aternal plasma concentrations 
after maternal dosage. This transplacental gradient was re­
ported to be due to the placenta itself (e.g\, active transport 
from fetus to mother, irreversible placental metabolic elimi­
nation), because fetal renal elimination did not play an im­
portant role (Mihaly et al., 1983). In a follow-up study the 
transplacental gradient could not be explained by a low pla­
cental permeability or differential plasma protein binding of 
cimetidine between mother and fetus (Ching et al., 1985).
Cimetidine, administered to women at labor, showed a
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slow placental transfer finally achieving equal concentra­
tions in maternal and fetal plasma. Protein binding or pla­
cental metabolism was of minor influence. Because the con­
centration of cimetidine in the amniotic fluid increased 
together with a decreasing concentration in the cord blood, a 
role for fetal renal elimination seemed likely (Howe et al., 
1981). However, because the fetal kidney begins to excrete 
waste products approximately 5 months after conception, the 
placenta could play a role in the elimination of cationic drugs 
before 5 months.
In the perfused human placental cotyledon, the clearance 
of cimetidine was low, providing evidence for a barrier func­
tion of the placenta in cimetidine transfer (Ching et al. ,
1987). Because fetal and maternal plasma concentrations did 
equilibrate, active transport appeared to play an insignifi­
cant role in maintaining a barrier across the human pla­
centa. The absence of mediated transport was confirmed by 
Schenker et al. (1987) by use of the same experimental tech­
nique. The maternal to fetal transfer of cimetidine showed no 
signs of accumulation, saturability or susceptibility to inhi­
bition by structural analogs. In this study, no evidence was 
found also for the saturation of cimetidine uptake in microvil­
lus membrane vesicles of human term placenta. However,
ABBREVIATIONS: FCCP, carbonyl cyanide p-trifluoromethoxyphenylhydrazone; Hepes, N-2-hydroxyethylpiperazine-N-2-ethanesulfonic acid; 
Mes, 2-(N-morpholino)ethanesulfonic acid; M0, starting mince; NMN, n-methylnicotinamide; pH,, pH inside the vesicle; pH0, pH outside the vesicle; 
SMMV, syncytial microvillus membrane vesicles; TEA, tetraethylammonium; Tris, 2-amino-2-hydroxymethylpropane-1,3-dioi; val, valinomycin.
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concentrations of up to only 400 /xM were used and no driving 
forces were applied.
More precise inform ation concerning the  driving forces, 
specificity and saturab ility  of transport could provide better 
insight into the  underlying mechanism of the low clearance 
for cimetidine across the  h um an  placenta. The present study 
was designed to investigate in  more detail the molecular 
m echanism s of cimetidine transport across the hum an term 
placenta bj  iv iug isolated SMMV.
Materials and Methods
V esicle p re p a ra tio n . Human placental SMMV were prepared 
according to a modification of the procedure described by Glazier et 
al. (1988) as method number three. Briefly, tissue obtained within 15 
min after uncomplicated delivery was minced in a Waring blender 
and stirred for 30 min to loosen the microvilli. After MgCl2 aggrega­
tion and differential centrifugation, both steps repeated once, SMMV 
were harvested and suspended in an appropriate buffer. The protein 
concentration of SMMV used in this study was 10,4 ± 2.2 mg/ml 
t?z. = 23). All subsequent steps were performed a t 4°C. Vesicles were 
frozen in N2(l) and stored a t — 80°C for 4 weeks at the maximum. 
Protein was assayed with a Coomassie blue kit (Biorad, München, 
Germany). Alkaline phosphatase enrichment of SMMV, measured 
according to Mircheff and Wright (1976), was 22-fold as compared 
with starting mince (M0: 60 ±  20, SMMV: 1350 ± 570 /xmol/h/mg, 
n = 14).
Uptake studies. Uptake of [3Hjcimetidine into SMMV was mea­
sured in quadruplicate a t 37°C with a rapid filtration technique 
(Russel et al., 1988). Uptake was started by addition of 10 jml mem­
brane suspension to 40 fil extravesicular medium containing radio- 
labeled compound. The transport conditions are given in the legends. 
At appropriate time intervals, the reaction was terminated by adding 
2 ml of ice-cold stop solution with the same composition as the 
intravesicular medium, except for membrane binding studies in 
which the stop solutions were equal to the corresponding extrave­
sicular media. The samples were filtered under vacuum through a 
Whatman GF/F glass fiber filter and washed 3-fold. Radioactivity 
remaining at the filter was counted in a Beckman LS 6000 LL liquid 
scintillation counter. Corrections were made for nonspecific filter 
binding.
D ata  analysis. Data are presented as means ± S.D,, with n 
representing the number of experiments with different vesicle prep­
arations. Statistical significance of differences in cimetidine uptake 
was determined with the use of two-tailed, paired Student’s ¿-test (P 
< .05). Curve fitting was done by least squares nonlinear regression 
analysis with the computer program PCNONLIN (Metzler and 
Weiner, 1989).
Chemicals. [3H]-L~alanine (77 Ci/mmol) was obtained from New 
England Nuclear (Dreieich, Germany) and [3H]cimetidine (21 Cl/ 
mmol) from Amersham (Aylesbury, U.K.). Cimetidine was gener­
ously donated by Smith, Kline & French Laboratories (Herts, U.K.), 
nizatidine by Eli Lilly & Company (Indianapolis, IN) and tri­
methoprim by Bergel (the Netherlands). Mepiperphenidol and famo­
tidine were generously donated by Merck, Sharpe & Dohme (Rah­
way, NY). NMN and TEA were purchased from Janssen Chimica 
(Beerse, Belgium). All other chemicals were purchased from either 
Sigma (St Louis, MO), Merck (Darmstadt, Germany) or Boehringer 
(Mannheim, Germany). GF/F filters were obtained from Whatman 
Int. Ltd (Maidstone, U.K.).
Results
H -grad ient-dependent up take of cim etid ine. The
outwardly directed proton gradient (pHj = 6.0/pHo = 7.4) 
stim ulated cimetidine (20 juM) up take into SMMV, resulting 
in a small, b u t  significant, tran s ien t overshoot (peak vs.
equilibrium = 1.3) as compared with uptake in the absence of 
a H +-gradient (pH; — pH(, = 7.4) (fig. 1). The difference in 
equilibrium uptake at 60 min is probably due to a pH-depen- 
dent increase in vesicle volume, but this should have minor 
effects on initial uptake values.
Effect of ionopliores on H +-gradient uptake. To de­
termine whether the stimulated uptake of cimetidine in the 
presence of a proton gradient was due to the activity of an 
organic cation-proton antiport system or a H ‘ -diffusion po­
tential, the effect of the proton ionophore FCCP was evalu­
ated. FCCP causes an enhanced H 'f‘-flux down its concentra­
tion gradient, which lowers the availability of H H for a 
possible cation-proton exchanger and consequently decreases 
the uptake of the cation. The FCCP-induced H ‘ -flux also 
renders the inside of the vesicle more negative resulting in an 
increase of uptake of the cation if uptake is dependent on a 
H'‘‘-diffusion potential. As shown in table 1, FCCP did not 
increase the IT* -gradient-dependent initial and peak uptake 
rates. These results show th a t an inside negative H"1 -diffu­
sion potential is unlikely to be a driving force for cimetidine 
uptake. However, in voltage-clamped vesicles (equal 
amounts of potassium at both sides of the membrane in 
presence of the K +-ionophore valinomycin), in which peak 
and equilibrium uptakes were not significantly altered, 
FCCP was able to decrease cimetidine uptake, resulting in a 
diminished overshoot. The decreased uptake suggests an or­
ganic cation-proton exchanger responsible for the small tran­
sient overshoot.
Determ ination o f membrane binding. Figure 2 shows 
that the uptake of 20 /xM cimetidine was inversely related to 
medium osmolarity (R2 >  .81 of individual regression lines), 
indicating transport into an osmotically responsive intrave­
sicular space. Because of the large variation in the uptake 
data between different placentas, only a rough estimate 
could be made of the actual intravesicular uptake, which 
accounted for 77 ± 27% of total uptake.
Effect of organic cations. The inhibitory effect of various 
organic cations on cimetidine uptake was investigated. Table 
2 shows the initial H*-gradient-dependent uptake of 20 ¡M 
[3H]cimetidine as percentage of representative control up­
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Fig. 1. Time-dependent uptake of 20 /¿M pHJcimetidine into SMMV in 
the presence or absence of an outwardly directed H * -gradient. Vesi­
cles were suspended in 300 mM mannitol and 10 mM Mes-Tris, pH =
6.0 or 10 mM Hepes-Tris, pH = 7.4. Extravesicular medium consisted 
of 300 mM mannitol and 10 mM Hepes-Tris, pH 7.4. Values are 
expressed as picomoles per milligram protein (n -  11).
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TABLE 1
Effect of H+-gradients and ionophores on cimetidine uptake
Uptake of 20 /xM [3H]cimetidine into vesicles suspended in  300 mM mannito! and 
10 mM Hepes-Tris, pH = 7.4, or 10 mM Mes-Tris, pH « 6.0 (A) or 100 mM 
mannitol, 100 mM KCl and 10 mM Mes-Tris, pH = 6.0 (B). Extravesicular media 
consisted of 300 mM mannitol and 10 mM Hepes-Tris, pH = 7.4 (A) or 100 mM 
mannitol, 100 mM KCl and 10 mM Hepes-Tris, pH = 7.4 (B). Vesicles were 
preequilibrated for 60 min at 37°C with 20 ¡M  valinomycin (val) and/or 40 ju.M 
PCCP. FCCP (40 /lcM) was also added to the extravesicular medium. Data are 
presented as pmol/mg protein (n = 3).
Uptake
Condition
10 sec 60 sec 60 min
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67 ±23
176 ± 34 
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148 ± 26 
154 ± 18
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Fig. 2. Effect of increasing osmotic pressure on uptake at 30 min of 20 
/¿M pHJcimetidine Into SMMV. Vesicles were suspended in 300 mM man­
nitol and 10 mM Hepes-Tris, pH -  7.4. Extravesicular media consisted of 
10 mM Hepes-Tris, pH = 7.4, and increasing concentrations of mannitol. 
Values of three placentas are expressed individually as picomoles per 
milligram protein versus reciprocal osmolarity of the final concentration.
TABLE 2
Effect of various organic cations on cimetidine uptake
Effect of various organic cations (1 or 5 mM) on the 30-sec uptake of 20 ¡iM 
pHJcimetidine in the presence of an outwardly directed H ' -gradient. Experimen­
tal conditions were similar to those given in the legend of figure 1. Uptakes are 
expressed relative to their own control uptakes, namely, without inhibitor at the 
same time and from the same placenta (n = 4). Mean control uptake was 112 ± 
30 pmol/mg protein (n = 10).
nizatidine and famotidine were able to inhibit cimetidine 
uptake partially, but significantly. The endogenous organic 
cation, NMN, decreased cimetidine uptake also, whereas cho­
line and guanidine did not.
Kinetics of cimetidine uptake* The presence of medi­
ated uptake was further investigated by evaluating the ini­
tial uptake of increasing concentrations of cimetidine in the 
presence of an outwardfy directed H +-gradient, The relation 
between cimetidine concentration and uptake rate was non­
linear. Total uptake corrected for estimated nonsaturable 
uptake showed saturability as can be seen in figure 3, Kinetic 
parameters were determined by fitting an equation combin­
ing Michaelis-Menten and linear kinetics v ~ VmDX'S/(Km +
* P < .05.
organic cation transport inhibitors mepiperphenidol and 
amiloride and several other cationic compounds, like tri­
methoprim, TEA and the H2-receptor antagonists ranitidine,
S) + k -S to the data, where v is the initial cimetidine uptake 
rate and S  is the cimetidine concentration. Nonlinear regres­
sion analysis revealed a Km of 6.3 ± 4.4 mM, a Vmax of 17.5 
± 10,2 nmol/mg/10 sec and a k of 1.6 ± 0.3 nmol/mg/10 
sec/mM,
Discussion
In human in vivo studies and in the artificially perfused 
human placental cotyledon, no evidence was found for medi­
ated transport of cimetidine (Howe et aL, 1981; Ching et aZ.} 
1987). It was concluded that transfer of cimetidine across the 
human placental trophoblast occurs by passive diffusion. 
However, if diffusional transfer quantitatively exceeds up­
take via a mediated pathway, the latter will be masked and 
not detected in these type of studies. Therefore, isolated 
membrane vesicles are a more appropriate tool to investigate 
whether mediated transport occurs across the plasma mem­
brane.
Our results in human placental SMMV show that cimeti­
dine transfer across the syncytial microvillus membrane of 
the human term placenta will be mainly due to passive 
diffusion, confirming the results obtained by others (Howe et 
al., 1981, Ching et a l 1987, Schenker et al., 1987). However, 
a small, but significant part oi total cimetidine uptake into 
SMMV could be attributed to mediated uptake, because up­
take was pH-dependent, inhibitable by several organic cat­
ions and saturable. Because the proton ionophore, FCCP, 
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Fig. 3. Concentration-dependent uptake of [3H]cimetidine at 10 sec 
into SMMV in the presence of an outwardly directed H+-gradient. 
Experimental conditions were the same as described in the legend of 
figure 1. Cimetidine concentrations ranged from 10 ¡M  to 20 mM. 
Values are expressed as nanomoles per milligram protein (n = 3).
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under voltage-clamped conditions, we suggest the presence of 
an  organic cation-proton an tiport system for cimetidine in 
hum an  placental SMMV, responsible for the small part of 
m ediated uptake. Cimetidine itse lf has been reported to in­
terfere w ith  the  hum an  placental Na^/H*-exchanger present 
in  the  syncytial microvillus m em brane, in  a  reversible man­
ner and competitive w ith respect to N a+ (Ganapathy et al. , 
1986). I t seems possible th a t  cimetidine, in  the presence of a 
H +~gradient, is transported  by th is Na^/H"1"-exchanger. The 
inhibition of cimetidine up take we observed in presence of 
the N a +/H +-exchange inhibitor amiloride would support 
such a view. However, th is  cationic drug is not a selective 
inhibitor, because it also inhibits organic cation transport in 
hum an placental and rabbit renal cortical brush-border 
m em brane vesicles (G anapathy et a l., 1988; Miyamoto et al., 
1989). The inhibition of guanidine uptake into renal cortical 
brush-border m em brane vesicles by cimetidine (Miyamoto et 
al., 1989) has not been found in  hum an placental brush- 
border m em brane vesicles (G anapathy et a l. , 1988). Because 
guanidine did not inh ib it cimetidine uptake significantly in 
our experiments, the  guanidine analog cimetidine is not 
likely to he transported  by the guanídine-proton antiport 
system presen t in h u m an  placental SMMV (Ganapathy et ah ,
1988). Cimetidine did inhibit m em brane potential-dependent 
choline up take  into SMMV (van der Aa et al., 1994), In 
contrast, choline was not able to inhibit cimetidine uptake 
significantly in  the p resen t study. Therefore i t  is also un­
likely th a t  cimetidine is transported  by the  choline carrier.
The affinity of the  system  is low, as can be concluded from 
a K m of 6.3 mM characterizing the  concentration-dependent 
uptake of cimetidine. The clinical relevance of this low-affin- 
ity system w ith respect to the  use of H 2-receptor antagonists 
during pregnancy seems therefore limited in terms of a pos­
sible accum ulation into the  trop hob la s t or extensive elimina­
tion from fetal to m ate rna l circulation. Such a low-affinity 
transport system  in microvillus m em branes would only make 
sense in  combination w ith  a high-affinity system in basal 
membranes. From  in vivo and perfused cotyledon experi­
m ents no evidence is available for the presence of such a 
system (Howe et a l., 1981; Schenker et a l. , 1987).
We therefore conclude th a t  the  system cannot be an im­
portan t factor in  the b a rrie r  function of the hum an placenta 
in the tran sp o rt of cimetidine as observed by Ching et al. 
(1987). Thus, active tran sp o rt can indeed be ruled out in 
m aintain ing such a barrier. O ther factors, as for instance the 
degree of ionization of cimetidine (pKa = 6.8) a t physiological 
pH, are probably of more importance to the  low clearance of 
cimetidine across the  h um an  placental trophoblast.
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